Comparing a new scan to standard scan during head and neck cancer radiation
Part of Cancer, Ear, nose & throat, Lungs & breathing, Mouth & dental clinical trials.
This trial is testing whether a newer type of PET/CT scan (F-18 NaF) can better detect blood vessel problems caused by radiation therapy than the standard scan (F-18 FDG) in people with head and neck cancer. If successful, it could lead to better ways to prevent and manage these complications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a specific type of head and neck cancer (squamous cell carcinoma) that is at an advanced stage or related to HPV, and your treatment plan includes radiation and chemotherapy (but not surgery) to try to cure the cancer.
- You are able to have the study scans and follow-up procedures.
- Women who could become pregnant must have a negative pregnancy test and agree to use effective birth control during the study.
- You must not be pregnant, a prisoner, or unable to give consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests whether giving a less intense (de-escalated) radiation plan can work for certain people with HPV-related oropharyngeal throat cancer. It uses HPV blood testing and scans to help guide treatment, aiming to keep cancer control while reducing treatment side effects.
This trial tests whether a lower dose of radiation to the neck is safe and effective for people with HPV-related oropharyngeal cancer. It may reduce side effects while still treating the cancer.
This study tests a way to use less radiation for HPV-related throat cancer. Doctors will adjust your treatment based on a simple blood test that tracks cancer DNA, so you may get only the treatment you need.
This Phase 2 trial tests whether planning radiation based on an imaging scan (F-MISO PET) can better target oxygen-poor (low-oxygen) tumor areas in head and neck cancer. It may help make radiation more precise while still using standard curative treatment.
This trial compares two treatments for advanced head and neck cancer in patients who cannot take the drug cisplatin. One group gets radiation plus a targeted drug called cetuximab, the other gets radiation plus standard chemotherapy. The goal is to see which approach works better and is safer for people who are not candidates for cisplatin.
This trial tests whether we can safely use lower doses of radiation for people with HPV-related throat cancer, while still targeting the areas that need it. The goal is to reduce side effects without lowering the chance of a cure.
Hear when a new Head and Neck Squamous Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.